ReviewCureus2025
Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a promising therapeutic option for patients with concurrent type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). This systematic review and meta-analysis evaluated the efficacy of empagliflozin on liver enzymes and metabolic parameters in this dual-pathology population. A comprehensive search was conducted across PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science databases from inception to July 2025. Randomized controlled trials (RCTs) comparing empagliflozin with placebo in adults with T2DM and NAFLD were included. Primary outcomes included changes in liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), while secondary outcomes comprised systolic blood pressure (SBP) and glycated hemoglobin (HbA1c) levels. Four studies met the inclusion criteria, encompassing 393 participants (206 empagliflozin, 187 control) with follow-up periods ranging from 20 to 24 weeks. Meta-analysis demonstrated significant reductions in ALT (mean difference (MD): -11.61; 95% confidence interval (CI): -19.18 to -4.04), AST (MD: -10.31; 95% CI: -15.41 to -5.21), and GGT levels (MD: -15.19; 95% CI: -18.13 to -12.25) with empagliflozin treatment compared to placebo. However, no statistically significant differences were observed for SBP (MD: -0.87; 95% CI: -7.93 to 6.20) or HbA1c (MD: -0.44; 95% CI: -1.10 to 0.22). Considerable heterogeneity was noted across studies for most outcomes. These findings suggest that empagliflozin offers hepatoprotective benefits in patients with concurrent T2DM and NAFLD, primarily through significant improvements in liver enzyme profiles. However, larger long-term studies with histological endpoints are needed to establish definitive clinical recommendations for this therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.